In this non-inferiority study, 108 patients with type 1 diabetes were randomly allocated to either an AI-managed group that received insulin treatments using the AI system or a manually managed group that received insulin treatments by a diabetes specialist. The gene discussed is INS; the disease is diabetes mellitus.